Citicoline oral solution in glaucoma: Is there a role in slowing disease progression?

Ophthalmologica

Volumn 229, Issue 4, 2013, Pages 219-226

  Ottobelli, L ^a   Manni, G L ^b,c   Centofanti, M ^b,c   Iester, M ^d   Allevena, F ^d   Rossetti, L ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c IRCCS FONDAZIONE BIETTI   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

Citicoline; Glaucoma; Visual field rate of progression

Indexed keywords

CITICOLINE; NEUKRON OFTA; UNCLASSIFIED DRUG; NOOTROPIC AGENT;

AGED; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; MALE; MULTICENTER STUDY; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL FIELD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECTS; GLAUCOMA, OPEN-ANGLE; INTRAOCULAR PRESSURE; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; PERIMETRY;

ADMINISTRATION, ORAL; AGED; CYTIDINE DIPHOSPHATE CHOLINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; NOOTROPIC AGENTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL FIELDS;

EID: 84876457566     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000350496     Document Type: Article

References (39)

1. Magnitude and causes of visual impairment. Fact sheet No 282, November 2004. http//www. who. int/mediacentre/factsheets/fs282/en/(accessed February 8, 2006).
2. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M: Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120: 1268-1279.
3. The Advanced Glaucoma Intervention Study (AGIS). 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000; 130: 429-440.
4. Maier PC, Funk J, Schwarzer G, Antes G, Falck-Ytter YT: Treatment of ocular hypertension and glaucoma: meta-analysis of randomised controlled trials. BMJ 2005; 331: 134.
5. Foganolo P, Rossetti L: Medical treatment of glaucoma: present and future. Expert Opin Investig Drugs 2011; 20: 947-959.
6. Medeiros FA, Alencar LM, Zangwill LM, Sample PA, Weinreb RN: The relationship between intraocular pressure and progressive retinal nerve fiber layer loss in glaucoma. Ophthalmology 2009; 116: 1125-1133.
7. Medeiros FA, Alencar LM, Sample PA, Zangwill LM, Susanna R Jr, Weinreb RN: The relationship between intraocular pressure reduction and rates of progressive visual field loss in eyes with optic disc hemorrhage. Ophthalmology 2010; 117: 2061-2066.
8. De Moraes CG, Demirel S, Gardiner SK, Liebmann JM, Cioffi GA, Ritch R, Gordon MO, Kass MA: Effect of treatment on the rate of visual field change in the ocular hypertension treatment study observation group. Invest Ophthalmol Vis Sci 2012; 53: 1704-1709.
9. Chauhan BC, Mikelberg FS, Artes PH, Balazsi AG, LeBlanc RP, Lesk MR, Nicolela MT, Trope GE: Canadian Glaucoma Study. 3. Impact of risk factors and intraocular pressure reduction on the rates of visual field change. Arch Ophthalmol 2010; 128: 1249-1255.
10. Sommer A: Intraocular pressure and glaucoma. Am J Ophthalmol 1989; 107: 186-188.
11. Baltmr A, Duggan J, Nizari S, Salt TE, Cordeiro MF: Neuroprotection in glaucoma-is there a future role? Exp Eye Res 2010; 91: 554-566.
12. Cheung W, Guo L, Cordeiro MF: Neuroprotection in glaucoma: drug-based approaches. Optom Vis Sci 2008; 85: 406-416.
13. Osborne NN: Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol 2009; 87: 450-454.
14. Secades JJ, Lorenzo JL: Citicoline: pharmacological and clinical review, 2006 update. Methods Find Exp Clin Pharmacol 2006; 28 suppl B:1-56.
15. Hazama T, Hasegawa T, Ueda S, Sakuma A: Evaluation of the effect of CDP-choline on poststroke hemiplegia employing a doubleblind controlled trial. Assessed by a new rating scale for recovery in hemiplegia. Int J Neurosci 1980; 11: 211-225.
16. Spiers PA, Myers D, Hochanadel GS, Lieberman HR, Wurtman RJ: Citicoline improves verbal memory in aging. Arch Neurol 1996; 53: 441-448.
17. Alvarez XA, Laredo M, Corzo D, Fernández-Novoa L, Mouzo R, Perea JE, Daniele D, Cacabelos R: Citicoline improves memory performance in elderly subjects. Methods Find Exp Clin Pharmacol 1997; 19: 201-210.
18. Shimamoto K, Hirano T, Aramaki Y: Therapeutic mechanism of cytidine diphosphate choline (CDP-choline) in parkinsonism. J Takeda Res Lab 1975; 34: 440-448.
19. Ruggieri S, Zamponi A, Casacchia M, Agnoli A: Effetti terapeutici della citicolina (citidindifosfo-colina) nella sindrome parkinsoniana. Clin Ter 1976; 78: 515-525.
20. Agnoli A, Ruggieri S, Denaro A, Bruno G: New strategies in the management of Parkinson's disease: a biological approach using a phospholipid precursor (CDP-choline). Neuropsychobiology 1982; 8: 289-296.
21. Fresina M, Dickmann A, Salerni A, De Gregorio F, Campos EC: Effect of oral CDP-choline on visual function in young amblyopic patients. Graefes Arch Clin Exp Ophthalmol 2008; 246: 143-150.
22. Porciatti V, Schiavi C, Benedetti P, Baldi A, Campos EC: Cytidine-5 ?-diphosphocholine improves visual acuity, contrast sensitivity and visually evoked potentials of amblyopic subjects. Curr Eye Res 1998; 17: 141-148.
23. Campos EC, Bolzani R, Schiavi C, Baldi A, Porciatti V: Cytidin-5 ?-diphosphocholine enhances the effect of part-time occlusion in amblyopia. Doc Ophthalmol 1996; 93: 247-263.
24. Campos EC, Schiavi C, Benedetti P, Bolzani R, Porciatti V: Effect of citicoline on visual acuity in amblyopia: preliminary results. Graefes Arch Clin Exp Ophthalmol 1995; 233: 307-312.
25. Parisi V, Coppola G, Ziccardi L, Gallinaro G, Falsini B: Cytidine-5 ? ?-diphosphocholine (citicoline): a pilot study in patients with nonarteritic ischaemic optic neuropathy. Eur J Neurol 2008; 15: 465-474.
26. Parisi V, Manni G, Colacino G, Bucci GM: Cytidine-5 ?-diphosphocholine (citicoline) improves retinal and cortical responses in patients with glaucoma. Ophthalmology 1999; 106: 1126-1134.
27. Parisi V: Electrophysiological assessment of glaucomatous visual dysfunction during treatment with cytidine-5 ?-diphosphocholine (citicoline): a study of 8 years of follow-up. Doc Ophthalmol 2005; 110: 91-102.
28. Virno M, Pecori-Giraldi J, Liguori A, De Gregorio F: The protective effect of citicoline on the progression of the perimetric defects in glaucomatous patients (perimetric study with a 10-year follow-up). Acta Ophthalmol Scand Suppl 2000; 232: 56-57.
29. Rejdak R, Toczolowski J, Kurkowski J, Kaminski ML, Rejdak K, Stelmasiak Z, Grieb P: Oral citicoline treatment improves visual pathway function in glaucoma. Med Sci Monit 2003; 9:PI24-PI28.
30. Grieb P, Rejdak R: Pharmacodynamics of citicoline relevant to the treatment of glaucoma. J Neurosci Res 2002; 67: 143-148.
31. Pecori-Giraldi J, Virno M, Covelli G, Grechi G, De Gregorio F: Therapeutic value of citicoline in the treatment of glaucoma (computerized and automated perimetric investigation). Int Ophthalmol 1989; 13: 109-112.
32. Roda A, Fini A, Grigolo B: Routes of administration and serum levels of (methyl C14) citicoline. Curr Ther Res Clin Exp 1983; 4: 1050-1053.
33. Rossetti L, Goni F, Denis P, Bengtsson B, Martinez A, Heijl A: Focusing on glaucoma progression and the clinical importance of progression rate measurement: a review. Eye 2010; 24:S1-S7.
34. Secades JJ, Frontera G: CDP-choline: pharmacological and clinical review. Methods Find Exp Clin Pharmacol 1995; 17(suppl B):1-54.
35. Weiss GB: Metabolism and actions of CDPcholine as an endogenous compound and administered exogenously as citicoline. Life Sci 1995; 56: 637-660.
36. Dávalos A, Alvarez-Sabín J, Castillo J, Díez-Tejedor E, Ferro J, Martínez-Vila E, Serena J, Segura T, Cruz VT, Masjuan J, Cobo E, Secades JJ, International Citicoline Trial on Acute Stroke (ICTUS) trial investigators: Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet 2012; 380: 349-357.
37. Cacabelos R, Caamaño J, Gómez MJ, Fernández-Novoa L, Franco-Maside A, Alvarez XA: Therapeutic effects of CDP-choline in Alzheimer's disease. Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors. Ann NY Acad Sci 1996 17; 777: 399-403.
38. Parisi V, Coppola G, Centofanti M, Oddone F, Angrisani AM, Ziccardi L, Ricci B, Quaranta L, Manni G: Evidence of the neuroprotective role of citicoline in glaucoma patients. Prog Brain Res 2008; 173: 541-554.
39. Quigley HA: Clinical trials for glaucoma neuroprotection are not impossible. Curr Opin Ophthalmol 2012; 23: 144-154.